Cargando…

Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system

BACKGROUND: Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that is now preferred in guidelines over angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for patients with heart failure with reduced ejection fraction (HFrE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Brendan J, Huang, Cheng-Wei, Chung, Joanie, Neyer, Jonathan R, Liang, Brannen, Yu, Albert S, Kwong, Eric K, Park, Joon S, Hung, Peggy, Sim, John J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372972/ https://www.ncbi.nlm.nih.gov/pubmed/36125061 http://dx.doi.org/10.18553/jmcp.2022.28.10.1173

Ejemplares similares

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

In silico study of inhibitory capacity of sacubitril/valsartan toward neprilysin and angiotensin receptor
por: Jovanović, Jelena Đorović, et al.
Publicado: (2022)

Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity
por: Boutagy, Nabil E., et al.
Publicado: (2020)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

Angiotensin II Receptor–Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats
por: Seki, Takunori, et al.
Publicado: (2017)

Effect of the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide
por: Ayalasomayajula, Surya, et al.
Publicado: (2018)

The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan
por: Jhund, Pardeep S, et al.
Publicado: (2016)

The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients
por: Stinkens, R., et al.
Publicado: (2018)

Improvement in quality of life with sacubitril/valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/Angiotensin) registry
por: Campal, José Manuel Rubio, et al.
Publicado: (2021)

Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real‐world study in Taiwan
por: Chang, Po‐Cheng, et al.
Publicado: (2020)

The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
por: Habibi, Javad, et al.
Publicado: (2019)

Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dual‐acting angiotensin receptor‐neprilysin inhibitor
por: Ushijima, Kentaro, et al.
Publicado: (2017)

Who ‘nose’, is it the angiotensin receptor neprilysin inhibitor?: a case series of persistent nasal pruritus in heart failure patients receiving sacubitril/valsartan
por: Gan, Jaclyn, et al.
Publicado: (2021)

The history and mystery of sacubitril/valsartan: From clinical trial to the real world
por: Zhang, Mingsong, et al.
Publicado: (2023)

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Neprilysin Inhibitor–Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice
por: Zhang, Hui, et al.
Publicado: (2019)

Real‐world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany
por: Wachter, Rolf, et al.
Publicado: (2019)

Real-World Usage of Sacubitril/Valsartan in Korea: A Multi-Center, Retrospective Study
por: Park, Jin Joo, et al.
Publicado: (2022)

Successful Treatment of Severe Heart Failure in Advanced Diabetic Kidney Disease Using Angiotensin–neprilysin Inhibitors (Sacubitril/Valsartan) – Report of Two Cases with Review of Options in Literature
por: Jha, Ratan, et al.
Publicado: (2021)

Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease—A Real-World Experience
por: Pereira, Sara C., et al.
Publicado: (2023)

Structure of neprilysin in complex with the active metabolite of sacubitril
por: Schiering, Nikolaus, et al.
Publicado: (2016)

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF
por: Visco, Valeria, et al.
Publicado: (2022)

Updated insights on dementia‐related risk of sacubitril/valsartan: A real‐world pharmacovigilance analysis
por: Chen, Congqin, et al.
Publicado: (2023)

Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)
por: Di Lenarda, Andrea, et al.
Publicado: (2023)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction
por: Fernandes, Amanda D.F., et al.
Publicado: (2021)

Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect
por: Kim, Heungjo, et al.
Publicado: (2022)

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
por: Polito, Maria Vincenza, et al.
Publicado: (2020)

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
por: Nordberg Backelin, Charlotte, et al.
Publicado: (2020)

Initial Real-World Practical Experience of Sacubitril/Valsartan Treatment in Japanese Patients With Chronic Heart Failure
por: Nakamura, Makiko, et al.
Publicado: (2021)

Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real‐world study
por: Chen, Wenwen, et al.
Publicado: (2021)

Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study
por: Wang, Chen, et al.
Publicado: (2023)

Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor
por: Teng, Yan, et al.
Publicado: (2023)

“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
por: Simpson, Joanne, et al.
Publicado: (2019)

Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uoukv29giriamjc7ac1k1mlj8m